Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma.

Pathobiology : journal of immunopathology, molecular and cellular biology - 1 Jan 2008

Yamanaka Sumitaka, Gu Zhaodi, Sato Masami, Fujisaki Rumi, Inomata Kenichi, Sakurada Akira, Inoue Akira, Nukiwa Toshihiro, Kondo Takashi, Horii Akira

Abstract excerpt

OBJECTIVE: To understand the molecular pathogenesis of lung cancer and to establish a novel therapeutic application, we examined the genetic alterations in lung cancer, and studied the effects of gefitinib and siRNA-mediated knockdown of EGFR on lung cancer. METHODS: We analyzed mutations in EGFR, KRAS, TP53, and ERBB2 in 198 surgically resected lung cancer specimens. We then analyzed the effects of gefitinib and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Silencing

Share to Gene Targeting

Share to Genes, ras

Share to Quinazolines

Share to Receptor, ErbB-2

Share to RNA, Small Interfering

Source

Identifiers

PMID: 18334834
DOI: 10.1159/000113789

Genes

EGFR
KRAS
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma.PMID 18334834Read ↗

Biological and clinical implications of EGFR mutations in lung cancer.Semantic proximity Read ↗

[Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma].Semantic proximity Read ↗

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.Semantic proximity Read ↗

Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology.Semantic proximity Read ↗

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.Semantic proximity Read ↗

Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.Semantic proximity Read ↗

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in small cell lung cancer.Semantic proximity Read ↗

Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma.Semantic proximity Read ↗

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.Semantic proximity Read ↗

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.